The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis

被引：0
|
作者：
Zohreh Safipour
Rogier van der Zanden
Joop van den Bergh
Paddy Janssen
Peter Vestergaard
Frank de Vries
Johanna H. M. Driessen
机构：
[1] Curaçao Medical Centre,Department of Clinical Pharmacy
[2] Maastricht University Medical Centre,Department of Clinical Pharmacy
[3] Maastricht University Medical Centre,Department of Internal Medicine
[4] Hasselt University,Faculty of Medicine and Life Science
[5] Viecuri Medical Centre,Department of Internal Medicine
[6] Viecuri Medical Centre,Department of Clinical Pharmacy
[7] Aalborg University Hospital,Departments of Clinical Medicines and Endocrinology
[8] Steno Diabetes Center North Jutland,MRC Lifecourse Epidemiology Unit
[9] Southampton General Hospital,Division of Pharmacoepidemiology and Clinical Pharmacology
[10] Utrecht Institute of Pharmaceutical Sciences,NUTRIM
[11] Cardiovascular Research Institute Maastricht (CARIM),School for Nutrition and Translational Research in Metabolism
[12] Maastricht University,undefined
来源：
Osteoporosis International | 2022年 / 33卷
关键词：
Glucocorticoids; Fracture; Bone; Myasthenia gravis; Case–control study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：649 / 658
页数：9
相关论文
共 50 条
  • [41] Risk factors of myasthenic crisis after thymectomy for thymoma patients with myasthenia gravis
    Xue, Liang
    Wang, Lin
    Dong, Jihong
    Yuan, Yunfeng
    Fan, Hong
    Zhang, Yi
    Wang, Qun
    Ding, Jianyong
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2017, 52 (04) : 692 - 697
  • [42] COMPARING ROC CURVE OF RISK WEIGHT CALCULATION WITH RISK RATIOS OF CANDIDATE RISK FACTORS FOR INCIDENT MAJOR OSTEOPOROTIC FRACTURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Yoshi, I.
    Sawada, N.
    Chijiwa, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83
  • [43] Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'' by Zheng
    Abtahi, Shahab
    Driessen, Johanna H. M.
    Burden, Andrea M.
    Souverein, Patrick C.
    van den Bergh, Joop P.
    van Staa, Tjeerd P.
    Boonen, Annelies
    de Vries, Frank
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (04)
  • [44] Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients
    McGurgan, Iain J.
    McGuigan, Christopher
    BRAIN AND BEHAVIOR, 2015, 5 (10):
  • [45] Increased risk of osteoporosis in patients with myasthenia gravis A population-based cohort study
    Yeh, Jiann-Horng
    Chen, Hsuan-Ju
    Chen, Yen-Kung
    Chiu, Hou-Chang
    Kao, Chia-Hung
    NEUROLOGY, 2014, 83 (12) : 1075 - 1079
  • [46] Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients
    Nguyen, Bella H. V.
    Kuo, James
    Budiman, Anadian
    Christie, Hayden
    Ali, Sayed
    MELANOMA RESEARCH, 2017, 27 (02) : 152 - 154
  • [47] Long-Term Bone Density Changes and Fracture Risk in Myasthenia Gravis: Implications for FRAX® Tool Application
    Konno, Shingo
    Uchi, Takafumi
    Kihara, Hideo
    Sugimoto, Hideki
    HEALTHCARE, 2024, 12 (17)
  • [48] Oral glucocorticoid use is associated with an increased risk of fracture
    Michael Steinbuch
    Thomas E. Youket
    Stanley Cohen
    Osteoporosis International, 2004, 15 : 323 - 328
  • [49] Oral glucocorticoid use is associated with an increased risk of fracture
    Steinbuch, M
    Youket, TE
    Cohen, S
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 (04) : 323 - 328
  • [50] Does diabetes modify the effect of FRAX risk factors for predicting major osteoporotic and hip fracture?
    W. D. Leslie
    S. N. Morin
    L. M. Lix
    S. R. Majumdar
    Osteoporosis International, 2014, 25 : 2817 - 2824
12345